Fig 2. Frequency of hand-foot syndrome (HFS) in the placebo and pyridoxine groups during the first three chemotherapy cycles. Fig 3. Cumulative dose of capecitabine until development of hand-foot ...

Hand-foot syndrome causes burning, pain, and swelling on the hands and feet. ... Topical silymarin administration for prevention of capecitabine-induced hand-foot syndrome: ...

Hand-foot syndrome (also known as hand-foot reaction, palmar-plantar erythrodysesthesia, chemotherapy-associated acral erythema or Burgdorf reaction) is a cutaneous toxicity1 – 3 that is most ...

The CNIO researchers found that patients who developed hand-foot syndrome during chemotherapy with capecitabine carried these regulatory variants that resulted in the reduced expression of CDH4 ...

Correlations between development of hand–foot syndrome (HFS) and efficacy in patients receiving capecitabine (CAP)-containing therapy are reported in the literature. We explored the relationship ...

PPE, otherwise known as hand–foot syndrome, is a cutaneous skin toxicity ... "PPE occurs in 6% to 42% of patients receiving fluorouracil, capecitabine, and doxorubicin," said session moderator ...

For example, hand-foot syndrome is one of the most common side effects of Xeloda. (For more about this condition, see “Hand-foot syndrome” above.) But severe skin reactions such as SJS and TEN ...

Hand-foot syndrome (HFS) is a frequently occurring adverse event associated with anticancer drugs. This study compares a newly introduced ointment containing several antioxidants and exhibiting high ...

Context. Certain chemotherapy drugs, notably capecitabine, can cause a side effect known as palmar-plantar erythrodysesthesia (hand-foot syndrome), a painful swelling and inflammation of the hands ...

This trial looked at whether vitamin B6 (pyridoxine) tablets could help relieve hand foot syndrome caused by the chemotherapy drug capecitabine. Doctors commonly use the chemotherapy drug capecitabine ...

Onquality Pharmaceuticals LLC has received FDA clearance of its IND application for OQL-036, a potential prophylactic treatment for capecitabine-induced hand-foot syndrome (HFS). BioWorld Science ...